Which reversal strategy is preferred to reverse neuromuscular blockade at the end of surgery in a pregnant patient?

Which reversal strategy is preferred to reverse neuromuscular blockade at the end of surgery in a pregnant patient?

• A. Neostigmine with Atropine
• B. Sugammadex
• C. Edrophonium
• D. Neostigmine alone

Answer: (A)

Reversing a nondepolarizing neuromuscular blocker in pregnancy aims to restore acetylcholine at the neuromuscular junction while preventing muscarinic side effects that could compromise both mother and fetus. Neostigmine increases acetylcholine to outcompete the blocker, and pairing it with an antimuscarinic like atropine blocks the unwanted muscarinic actions (such as bradycardia and excessive secretions) that neostigmine alone would cause. In obstetric cases, this combination provides a reliable and safe way to achieve adequate reversal with controlled maternal hemodynamics, which is essential for maintaining uteroplacental perfusion. While alternatives exist—sugammadex can reverse certain blockades quickly, its safety data in pregnancy are more limited, and edrophonium is shorter-acting and less predictable in depth of reversal—the neostigmine-atropine approach remains the standard by providing predictable reversal and manageable side effects. Neostigmine alone would leave muscarinic effects unopposed, and thus is not preferred.

Reversing a nondepolarizing neuromuscular blocker in pregnancy aims to restore acetylcholine at the neuromuscular junction while preventing muscarinic side effects that could compromise both mother and fetus. Neostigmine increases acetylcholine to outcompete the blocker, and pairing it with an antimuscarinic like atropine blocks the unwanted muscarinic actions (such as bradycardia and excessive secretions) that neostigmine alone would cause. In obstetric cases, this combination provides a reliable and safe way to achieve adequate reversal with controlled maternal hemodynamics, which is essential for maintaining uteroplacental perfusion. While alternatives exist—sugammadex can reverse certain blockades quickly, its safety data in pregnancy are more limited, and edrophonium is shorter-acting and less predictable in depth of reversal—the neostigmine-atropine approach remains the standard by providing predictable reversal and manageable side effects. Neostigmine alone would leave muscarinic effects unopposed, and thus is not preferred.